A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

Trial Details

NCT ID
NCT07128199
Phase
PHASE3
Sponsor
Taiho Oncology, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • TAS6417
  • Zipalertinib Matching-placebo
Locations (sample)
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • La Jolla, California, United States|32.84727,-117.2742
  • Vallejo, California, United States|38.10409,-122.25664

Key Eligibility Criteria

  • Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.
  • Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendment (CLIA) certified (United States \[…
  • exon20 insertion mutations (ex20ins) or
  • other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) exons 18-21 of the EGFR tyrosine kinase domain

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →